The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women.

Slides:



Advertisements
Similar presentations
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Advertisements

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D
Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women.
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D. 
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin.
Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome  Andréanne Trottier, B.Sc., Marie-Claude.
Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C)  Michael W. Pankhurst,
The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study  Jeff G. Wang, M.D., Richard A. Anderson,
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report  Ricardo Azziz, M.D., M.P.H., Enrico Carmina,
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis  Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,
Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome  Elisabeth Lerchbaum,
Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome 
MRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome.
Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women  Babak Mokhlesi, M.D.,
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters  Enrico Carmina, M.D., Francesco.
Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A
Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study  Cem Celik, M.D., Nicel.
The spectrum of androgen excess disorders
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome  Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,
Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study  Angela Kerchner, B.A., Whitney Lester,
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels 
Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary.
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach  Fatemeh Bazarganipour,
Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome  Héctor F. Escobar-Morreale,
Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.
Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.
Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study 
Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens 
Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis  Shiqin Zhu, M.D., Bingqian Zhang, M.D.,
Andrew C. Bjonnes, M.S., Richa Saxena, Ph.D., Corrine K. Welt, M.D. 
Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis  Francesca Moro, M.D., Clara De Simone,
Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS)  F. Gonzalez,
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity  Jean-Patrice Baillargeon, M.D.,
Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome  Macarena Alpañés, M.D., Manuel.
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Increased secretion of amylin in women with polycystic ovary syndrome
ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome  Lucas Bandeira Marchesan, B.Sc., Poli Mara Spritzer,
Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S
Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome  Carlos Moran, M.D.,
Antoni J. Duleba, M.D., Ibrahim M. Ahmed, M.D.  Fertility and Sterility 
Vasiliki A. Moragianni, M. D. , M. S. , Stephanie-Marie L. Jones, M. D
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment  Richard Fleming, Ph.D.,
Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial  Antoni J. Duleba, M.D.,
Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D
Serum resistin levels in women with polycystic ovary syndrome
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Manuel Maliqueo, Ph. D. , Bárbara Echiburú, Ph. D
High serum concentration of total inhibin in polycystic ovary syndrome
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Are patients with idiopathic hirsutism (IH) insulin resistant
Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions  Kristen Farrell, M.S.,
Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome  Yuwen Wu, M.D., Jianhua Zhang,
Current evaluation of amenorrhea
Inappropriate gonadotropin secretion in polycystic ovary syndrome
Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome  Mesut Ozkaya, Assistant Professor, Erman Cakal, Specialist, Yusuf.
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome 
Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients  Artemis Karkanaki,
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test  Dimitrios Panidis, M.D., Ph.D., Dimitrios.
Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome  Robert P. Kauffman,
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels 
Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis 
Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3  Wendy Chang, M.D.,
Presentation transcript:

The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism  Manuel Luque-Ramírez, M.D., Ph.D., Macarena Alpañés, M.D., Héctor F. Escobar-Morreale, M.D., Ph.D.  Fertility and Sterility  Volume 94, Issue 6, Pages 2214-2221 (November 2010) DOI: 10.1016/j.fertnstert.2009.11.049 Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 1 All factors and stepwise (probability for entry ≤.05, probability for removal ≥.10) multiple regression analysis of the logarithm of insulin sensitivity index, area under the curve (AUC) insulin-to-AUC glucose ratio and insulin secretion/insulin resistance (disposition) index. The circles correspond to the standardized regression coefficients (β, or the change in terms of standard deviations in the dependent variable that results from a change of one standard deviation in an independent variable) and the error bars indicate the 95% confidence interval of β. R2 = coefficient of determination. Smoking and family history of diabetes were coded as dummy variables (present = 1 or absent = 0). PCOS = polycystic ovary syndrome. Fertility and Sterility 2010 94, 2214-2221DOI: (10.1016/j.fertnstert.2009.11.049) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Differences in the influence of family history of type 2 diabetes on indexes of insulin sensitivity and β-cell function in patients with polycystic ovary syndrome (PCOS) and in controls who do not have hyperandrogenemia. Data are means ± 95% confidence intervals. The figures below the x-axis indicate the number of women in each subgroup. AUC = area under the curve of an oral glucose tolerance test. *P≤.05 for the interaction between PCOS and family history of diabetes, meaning that the influence of family history of diabetes was the opposite in patients with PCOS and in women who did not have hyperandrogenemia. †P≤.05 for the difference between patients with PCOS and women who did not have hyperandrogenemia, irrespective of family history of diabetes. ‡P≤.05 for the influence of family history of diabetes, irrespective of PCOS or nonhyperadrogenic status. Fertility and Sterility 2010 94, 2214-2221DOI: (10.1016/j.fertnstert.2009.11.049) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 3 All factors and likelihood ratio binary logistic regression analysis of the determinants of the presence or absence of abnormalities of glucose tolerance. The circles show the odds ratio and the error bars indicate the 95% confidence interval (CI) of the odds ratio. R2 = Nagelkerke's coefficient of determination. Smoking and family history of diabetes were coded as dummy variables (present = 1 or absent = 0). Fertility and Sterility 2010 94, 2214-2221DOI: (10.1016/j.fertnstert.2009.11.049) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions